NKGen Biotech, Inc. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 11 months to Dec 31, 2021
Revenues
Costs and expenses:
Cost of revenues
Research and development expenses
General and administrative
General and administrative expenses - related party
Franchise tax expenses
Total expenses
Loss from operations
Other income (expense):
Interest expense (including related party amounts of $431 and $2,271 for the year ended December 31, 2023 and 2022, respectively)
Change in fair value of convertible promissory notes and convertible promissory notes due to related parties (including related party amounts of $12 and $4 for the years ended December 31, 2023 and 2022, respectively)
Change in fair value of forward purchase derivative liability
Offering costs - derivative warrant liability
Loss upon issuance of private placement warrants
Gain from extinguishment of deferred underwriting commissions allocated to derivative warrant liability
Income from investments held in Trust Account
Interest expense (including related party amounts of $(1,620) and $(431) for the years ended December 31, 2024 and 2023, respectively)
Change in fair value of financial instruments (including related party amounts of $1,825 and $(12) for the years ended December 31, 2024 and 2023, respectively)
Loss on issuance of financial instruments (including related party amounts of $(639) and zero for the years ended December 31, 2024 and 2023, respectively)
Loss on amendments to financial instruments, net
Other, net
Total other income (expense)

Net loss before provision for income taxes
Provision for income taxes
Net loss
Earnings Per Share
Weighted-average common shares outstanding, basic (in shares)
Weighted-average common shares outstanding, diluted (in shares)
Net loss per share, basic (in usd per share)
Net loss per share, diluted (in usd per share)

Comments